Product Details
| Product Name:
Vantictumab |
CAS No.:
1345009-45-1 |
| Purity:
99% (SDS-PAGE); 97.7% (SEC-HPLC) |
Supply Ability:
10g |
| Release date:
2026/08/20 |
Product Introduction
Bioactivity
| Name | Vantictumab |
| Description | Vantictumab (OMP-18R5) is a humanized anti-FZD1/2/5/7/8 monoclonal antibody that binds to frizzled (FZD) receptors and inhibits Wnt pathway signaling. Vantictumab can be used in research on metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma. |
| In vitro | Method: MCF-7, T47D, 293T, SUM149, SUM159, Wnt-secreting L cells, MDA-MB-231, and MDA-MB-231_BH cells were incubated with vantictumab at a concentration of 50 μg/mL. Cells were cultured for 5 days (cell lines) or 7 days (primary samples), after which mammospheres with diameters greater than 50 μm were counted.
Result: Vantictumab inhibited Wnt signaling and reversed CM-induced mammosphere formation in early breast cancer samples in vitro. [1] |
| In vivo | Method: For subcutaneous xenograft experiments, 1 × 10⁶ MCF-7 cells were injected into each flank of female NSG mice. Mice were treated with vantictumab (15 mg/kg, intraperitoneal injection, once weekly) or control vehicle (sterile PBS), starting 3 days before tumor cell injection and continuing throughout the study period.
Result: Vantictumab-treated mice exhibited a significant reduction in ex vivo mammosphere formation by cells isolated from the femur compared with control mice. [1]
Method: A total of 5 × 10⁵ GFP- and luciferase-labeled MDA-MB-231_BH cells were injected intravenously via the tail vein into female BALB/c nude mice. Mice received intraperitoneal injections of vantictumab at a dose of 15 mg/kg once weekly.
Result: Vantictumab reduced spontaneous hindlimb bone metastasis in the MDA-MB-231_BH model. [1] |
| Storage | Store at low temperature
-20°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | βcatenin | Wnt/β-catenin | Wnt/betacatenin | Wnt/b-catenin | Wnt | beta-catenin | betacatenin | bcatenin |
| Inhibitors Related | Chlorquinaldol | Urea | Wnt pathway activator 1 | Neohesperidin | XAV-939 | Ethyl linoleate | Monensin sodium salt | Nimbolide | Isoquercetin | (±)-Nornicotine | Methyl Vanillate | Bisdemethoxycurcumin |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States